Advanced Analytical

Advanced Analytical Technologies, Inc. develops workflow solutions for nucleic acid analysis.

FA PromotionPromotionsFP Promotions

AATI develops and manufactures capillary electrophoresis based solutions for nucleic acid analysis. The instruments employ parallel capillary electrophoresis, with UV absorbance or fluorescence detection, to streamline nucleic acid analysis and alleviate analytic bottlenecks. AATI’s nucleic acid analysis solutions are ideal for any application, from NGS library QC and CRISPR/Cas9 mutation detection to determining oligonucleotide purity and genomic DNA analysis.

Upcoming Events

Mar 14 - 17
GFV 2018
28th Annual Meeting of the Society for Virology
Würzburg, DE
Mar 20 - 21
IowaBio Partnering for Growth
Partnering for Growth
Ankeny, IA
Mar 22 - 24
GBM
Mosbacher Kolloquium of the GBM
Mosbach, DE

Recent News

AATI Strikes Multiple New Alliances in 2017

Advanced Analytical Technologies, Inc. (AATI) entered into multiple new agreements over the course of 2017 most significantly with long- and short-read sequencer manufacturers. “Our mission is to bring unparalleled quality and service to our customers. These alliances allow AATI to fulfill its promise to help todays researchers reduce time to results through faster and more reliable QC workflows.” Said Steve Siembieda, VP of Commercialization.

AATI’s Mutation Screening Method for CRISPR Workflows Featured in GEN

Integration of an accurate and efficient mutation screening method into CRISPR/Cas genome editing workflows saves researchers time and money by eliminating unnecessary sequencing.

Genetic Engineering & Biotechnology News recently published a tutorial detailing our solution for CRISPR mutation screening and zygosity determination. Starting with the AccuCleave T7CE Kit, cleavage products are separated using the CRISPR Gel Discovery Kit on the Fragment Analyzer, followed by analysis using a custom plugin for PROSize Data Analysis Software. For more information, read the tutorial here.

AATI Featured in CRISPR Commentary

AATI’s own Steve Siembieda, Vice President of Commercialization, recently penned a commentary in DDNews on two primary issues in CRISPR genome editing: (1) low specificity and (2) low efficiency.  Put simply, CRISPR technology produces too many off-target mutations and does not have the success rate necessary for adoption into sensitive applications, notably the treatment of genetic illnesses.  The article went on to discuss potential remedies for low specificity and low efficiency in CRISPR workflows and the associated QC and mutation screening challenges.  The Fragment Analyzer supports these remedies and fulfills the QC and screening needs of CRISPR pipelines, accurately assessing the suitability of reagents and identifying and characterizing positive lines.

Top